Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Market Closed 10-04 16:00:00 EDT

5.09

-0.02

-0.39%

盘后5.09

+0.000.00%

16:01 EDT

High5.31	Low4.97	Vol196.00K
Open5.24	D1 Closing5.11	Amplitude6.66%
Mkt Cap312.36M	Tradable Cap186.28M	Total Shares61.37M
T/O991.17K	T/O Rate0.54%	Tradable Shares36.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":5.09,"timestamp":1728072000000,"preClose":5.11,"halted":0,"volume":195997,"hourTrading":{"tag":"盘后","latestPrice":5.09,"preClose":5.09,"latestTime":"16:01 EDT","volume":367,"amount":1868.03,"timestamp":1728072105943},"delay":0,"floatShares":36596360,"shares":61367509,"eps":-2.190008,"marketStatus":"Market Closed","change":-0.02,"latestTime":"10-04 16:00:00 EDT","open":5.24,"high":5.3101,"low":4.97,"amount":991172.2152,"amplitude":0.066556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.190008,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1728288000000},"marketStatusCode":7,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":5.11,"preHourTrading":{"tag":"盘前","latestPrice":5.11,"preClose":5.11,"latestTime":"08:23 EDT","volume":27,"amount":137.97,"timestamp":1728044594632},"postHourTrading":{"tag":"盘后","latestPrice":5.09,"preClose":5.09,"latestTime":"16:01 EDT","volume":367,"amount":1868.03,"timestamp":1728072105943},"volumeRatio":0.8152526116876159,"impliedVol":2.27,"impliedVolPercentile":0.7738},"requestUrl":"/m/hq/s/GLUE","defaultTab":"news","newsList":[{"id":"2466272275","title":"Monte Rosa Therapeutics Price Target Maintained With a $11.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2466272275","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466272275?lang=en_us&edition=fundamental","pubTime":"2024-09-12 20:51","pubTimestamp":1726145460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2024 08:51 ET (12:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"gpt_icon":0},{"id":"2466423288","title":"Tracking Baker Brothers Portfolio - Q2 2024 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2466423288","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466423288?lang=en_us&edition=fundamental","pubTime":"2024-09-11 11:54","pubTimestamp":1726026860,"startTime":"0","endTime":"0","summary":"Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter.New stakes include Summit Therapeutics and Alkermes plc, while ACADIA Pharmaceuticals, Madrigal Pharmaceuticals, and In","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4720332-tracking-baker-brothers-portfolio-q2-2024-update","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ABBV","ROIV","TCRX","INSM","ATHA","CERS","IE00BSNM7G36.USD","HOOK","SMMT","ARGX","INCY","MDGL","DNLI","IGMS","KOD","CERE","BCYC","ADAP","RVMD","EWTX","ABCL","NRIX","SGMT","STOK","AKRO","ACHL","TSVT","BMEA","ACAD","ALGS","GLUE","IMCR","AVTE","RARE","BCRX","BGNE","LU0234570918.USD","KYMR","IE00B19Z3581.USD","KALA","IMTX","RYTM","KNSA","LU0256863902.USD","OPT","TRDA","VTVT","REPL","ALKS"],"gpt_icon":1},{"id":"2462536924","title":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2462536924","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462536924?lang=en_us&edition=fundamental","pubTime":"2024-08-28 19:00","pubTimestamp":1724842800,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  28, 2024  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/28/2936883/0/en/Monte-Rosa-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","LU0267386448.USD","LU1720051108.HKD","BK4139","LU1989772923.USD","LU0225283273.USD","BK4504","LU0971096721.USD","LU1548497426.USD","GLUE","LU0106831901.USD","IE00BKVL7J92.USD","LU0098860793.USD","LU1720051017.SGD","BK4581","LU1074936037.SGD","LU0314104364.USD","BK4539","LU1668664300.SGD","BK4585","IE00BZ1G4Q59.USD","LU2357305700.SGD","LU1162221912.USD","LU0320765646.SGD","BK4127","LU1989772840.SGD","BK4588","BK4534"],"gpt_icon":0},{"id":"2460339450","title":"Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2460339450","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460339450?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:25","pubTimestamp":1724070304,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics  said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases.Initial results are due in Q1 2025, the company said.Monte Rosa said the study will assess the safety, pharmacokinetics, and target degradation of MRT-6160, intended to potentially treat autoimmune and inflammatory conditions by degrading proteins difficult to target with conventional drugs.Preclinical results have indicated \"encouraging results\" for MRT-6160 in models of rheumatoid arthritis and other autoimmune disorders, the company said.The company plans to use the phase 1 data to advance proof-of-concept studies in conditions like ulcerative colitis and rheumatoid arthritis, according to Chief Executive Markus Warmuth.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MRT","GLUE","BK4230","BK4539"],"gpt_icon":0},{"id":"2460334970","title":"Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2460334970","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460334970?lang=en_us&edition=fundamental","pubTime":"2024-08-19 20:25","pubTimestamp":1724070304,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["MRT","BK4139","GLUE","BK4539","BK4230"],"gpt_icon":0},{"id":"2460084967","title":"Monte Rosa Therapeutics Announces First Participants Dosed in Mrt-6160 Phase 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2460084967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460084967?lang=en_us&edition=fundamental","pubTime":"2024-08-19 19:00","pubTimestamp":1724065200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240819:nTUA4WKRZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2460084482","title":"Monte Rosa Therapeutics Inc - Mrt-6160 Phase 1 Clinical Results Anticipated Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2460084482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460084482?lang=en_us&edition=fundamental","pubTime":"2024-08-19 19:00","pubTimestamp":1724065200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240819:nTUA4WKRZB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2460608410","title":"Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2460608410","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460608410?lang=en_us&edition=fundamental","pubTime":"2024-08-19 19:00","pubTimestamp":1724065200,"startTime":"0","endTime":"0","summary":"MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases Init","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/19/2932006/0/en/Monte-Rosa-Therapeutics-Announces-First-Participants-Dosed-in-MRT-6160-Phase-1-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","MRT","GLUE","BK4139","BK4230"],"gpt_icon":0},{"id":"2459705069","title":"Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Immunovant (IMVT) and Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459705069","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459705069?lang=en_us&edition=fundamental","pubTime":"2024-08-13 20:24","pubTimestamp":1723551866,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molina Healthcare (MOH – Research Report), Immunovan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-molina-healthcare-moh-immunovant-imvt-and-monte-rosa-therapeutics-glue?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-molina-healthcare-moh-immunovant-imvt-and-monte-rosa-therapeutics-glue?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MOH","BK4154","BK4532","BK4539","IMVT","BK4588","SG9999014013.SGD","GLUE","SG9999014021.USD","SG9999014039.USD","BK4585","SG9999014005.SGD"],"gpt_icon":0},{"id":"2458603822","title":"Buy Rating Affirmed: Anticipated Catalysts and Undervaluation Set to Boost Monte Rosa Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2458603822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458603822?lang=en_us&edition=fundamental","pubTime":"2024-08-12 18:39","pubTimestamp":1723459178,"startTime":"0","endTime":"0","summary":"Analyst Derek Archila of Wells Fargo maintained a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report), reducing the price target to $17....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-anticipated-catalysts-and-undervaluation-set-to-boost-monte-rosa-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-anticipated-catalysts-and-undervaluation-set-to-boost-monte-rosa-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"gpt_icon":0},{"id":"2458932465","title":"Monte Rosa Therapeutics GAAP EPS of -$0.43, revenue of $4.7M","url":"https://stock-news.laohu8.com/highlight/detail?id=2458932465","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458932465?lang=en_us&edition=fundamental","pubTime":"2024-08-09 21:15","pubTimestamp":1723209345,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics press release : Q2 GAAP EPS of -$0.43. Collaboration Revenue of $4.7M, compared with $0 during the same period in 2023. Collaboration revenue represents revenue recorded under the Roche License and Collaboration agreement. Cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2024, were $267.1M, compared to cash, cash equivalents, restricted cash, and marketable securities of $197.8M as of March 31, 2024.  The company expects its cash and cash equivalents to be sufficient to fund planned operations and capital expenditures into the first half of 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4138086-monte-rosa-therapeutics-gaap-eps-of-0_43-revenue-of-4_7m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["GLUE"],"gpt_icon":0},{"id":"2458885303","title":"TD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2458885303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458885303?lang=en_us&edition=fundamental","pubTime":"2024-08-09 08:16","pubTimestamp":1723162597,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Marc Frahm maintained a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report) yesterday. The company’s shares closed yest...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","GLUE","COWN"],"gpt_icon":0},{"id":"2457168783","title":"Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2457168783","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457168783?lang=en_us&edition=fundamental","pubTime":"2024-08-08 20:15","pubTimestamp":1723119309,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics  came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.56 per share when it actually produced a loss of $0.53, delivering a surprise of 5.36%.Monte Rosa Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.7 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 46.58%. This compares to zero revenues a year ago.Monte Rosa Therapeutics shares have lost about 36.1% since the beginning of the year versus the S&P 500's gain of 9%.While Monte Rosa Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d6hN0_BhikrNdWTnix6fng--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d6hN0_BhikrNdWTnix6fng--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-glue-reports-121509655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLUE"],"gpt_icon":0},{"id":"2457094392","title":"Monte Rosa Therapeutics Q2 2024 GAAP EPS $(0.43) Beats $(0.55) Estimate, Sales $4.695M Beat $1.349M Estimate, Cash Position Of $267.1M Is Expected To Fund Operations Into H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2457094392","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457094392?lang=en_us&edition=fundamental","pubTime":"2024-08-08 20:12","pubTimestamp":1723119129,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Q2 2024 GAAP EPS $(0.43) Beats $(0.55) Estimate, Sales $4.695M Beat $1.349M Estimate, Cash Position Of $267.1M Is Expected To Fund Operations Into H1 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40250331/monte-rosa-therapeutics-q2-2024-gaap-eps-0-43-beats-0-55-estimate-sales-4-695m-beat-1-349m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Monte Rosa Therapeutics Q2 2024 GAAP EPS $(0.43) Beats $(0.55) Estimate, Sales $4.695M Beat $1.349M Estimate, Cash Position Of $267.1M Is Expected To Fund Operations Into H1 2027","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"gpt_icon":0},{"id":"2457995483","title":"Monte Rosa Therapeutics: Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2457995483","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457995483?lang=en_us&edition=fundamental","pubTime":"2024-08-08 19:15","pubTimestamp":1723115703,"startTime":"0","endTime":"0","summary":"BOSTON  — BOSTON  — Monte Rosa Therapeutics Inc.  on Thursday reported a loss of $30.3 million in its second quarter.The Boston-based company said it had a loss of 43 cents per share.The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 50 cents per share.The biopharmaceutical company posted revenue of $4.7 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $3.2 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-q2-earnings-111503282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLUE"],"gpt_icon":0},{"id":"2457930853","title":"BRIEF-Monte Rosa Therapeutics Q2 EPS USD -0.43","url":"https://stock-news.laohu8.com/highlight/detail?id=2457930853","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457930853?lang=en_us&edition=fundamental","pubTime":"2024-08-08 19:00","pubTimestamp":1723114847,"startTime":"0","endTime":"0","summary":"Aug 08 (Reuters) - Monte Rosa Therapeutics Q2 operating expenses USD 37.337 million. * Q2 pretax profit USD -30.058 million * Q2 operating income USD -32.642 million * Q2 net income USD -30.31 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USD","GLUE"],"gpt_icon":0},{"id":"2457396823","title":"Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2457396823","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457396823?lang=en_us&edition=fundamental","pubTime":"2024-08-08 19:00","pubTimestamp":1723114800,"startTime":"0","endTime":"0","summary":"IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial clinical ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/08/2926748/0/en/Monte-Rosa-Therapeutics-Announces-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CNS","BK4135","BK4139","GLUE"],"gpt_icon":0},{"id":"2449377783","title":"Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2449377783","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449377783?lang=en_us&edition=fundamental","pubTime":"2024-07-08 20:36","pubTimestamp":1720442160,"startTime":"0","endTime":"0","summary":"BOSTON, July  08, 2024  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/07/08/2909643/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-UBS-Targeted-Protein-Degradation-Day.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2449299196","title":"Recent uptick might appease Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) institutional owners after losing 39% over the past year","url":"https://stock-news.laohu8.com/highlight/detail?id=2449299196","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2449299196?lang=en_us&edition=fundamental","pubTime":"2024-07-05 19:16","pubTimestamp":1720178191,"startTime":"0","endTime":"0","summary":"Key Insights Given the large stake in the stock by institutions, Monte Rosa Therapeutics' stock price might be...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/recent-uptick-might-appease-monte-rosa-therapeutics-inc-nasd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2095319765.USD","NDAQ","NQmain","LU2210150020.SGD","BK4539","GLUE","BK4112","TQQQ","MNQmain","PSQ","QLD",".IXIC","LU2210149790.SGD","BK4585","BK4139","BK4588","QID","QQQ","SQQQ"],"gpt_icon":0},{"id":"2447363726","title":"Monte Rosa Therapeutics Price Target Maintained With a $16.00/Share by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2447363726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2447363726?lang=en_us&edition=fundamental","pubTime":"2024-06-29 01:47","pubTimestamp":1719596820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 28, 2024 13:47 ET (17:47 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":-0.0155},{"period":"1month","weight":-0.0959},{"period":"3month","weight":0.3984},{"period":"6month","weight":-0.2801},{"period":"1year","weight":0.1187},{"period":"ytd","weight":-0.0991}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.04},{"period":"3month","weight":0.0331},{"period":"6month","weight":0.1052},{"period":"1year","weight":0.3498},{"period":"ytd","weight":0.2055}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.156816},{"month":2,"riseRate":0.666667,"avgChangeRate":0.04993},{"month":3,"riseRate":0.666667,"avgChangeRate":0.124226},{"month":4,"riseRate":0,"avgChangeRate":-0.295044},{"month":5,"riseRate":0.333333,"avgChangeRate":0.036693},{"month":6,"riseRate":0.333333,"avgChangeRate":0.028435},{"month":7,"riseRate":0.75,"avgChangeRate":0.0647},{"month":8,"riseRate":0.5,"avgChangeRate":0.131017},{"month":9,"riseRate":0.25,"avgChangeRate":-0.16729},{"month":10,"riseRate":0.5,"avgChangeRate":-0.037807},{"month":11,"riseRate":0,"avgChangeRate":-0.11321},{"month":12,"riseRate":0.666667,"avgChangeRate":0.257702}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}